Abstract
Little is known about prevalence of drug resistance among HIV-infected Ugandans, a setting with over 15 years of public sector access to antiretroviral therapy (ART) and where virological monitoring was only recently introduced. This study was conducted in the adults' out-patient clinic of the Infectious Diseases Institute, Kampala, Uganda. HIV genotyping was performed in ART-naive patients and in treatment-experienced patients on ART for ≥6 months with virological failure (≥1000 copies/mL). A total of 152 ART-naive and 2430 ART-experienced patients were included. Transmitted drug resistance was detected in 9 (5.9%) patients. After a median time on ART of 4.7 years [interquartile range: 2.5-8.7], 190 patients (7.8%) had virological failure with a median viral load of 4.4 log10 copies per milliliter (interquartile range: 3.9-4.9). In addition, 146 patients had a viral load between 51 and 999 copies per milliliter. Most patients with virological failure (142, 74.7%) were on first-line ART. For 163 (85.8%) ART-experienced patients, genotype results were available. Relevant drug-resistance mutations were observed in 135 (82.8%), of which 103 (63.2%) had resistance to 2 drug classes, and 11 (6.7%) had resistance to all drug classes ...Continue Reading
References
Mar 29, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Charles KabugoPaul J Weidle
Jun 27, 2009·The Lancet Infectious Diseases·Ravindra K GuptaDeenan Pillay
Feb 27, 2010·The Lancet Infectious Diseases·Roos E BarthAnnemarie M J Wensing
Nov 13, 2010·International Journal of Epidemiology·Raph L HamersUNKNOWN PharmAccess African PASER and TREAT Asia Studies to Evaluate Resistance
Jul 26, 2012·Lancet·Ravindra K GuptaSilvia Bertagnolio
Jul 31, 2012·BMC International Health and Human Rights·Solomon NwakaTshinko Ilunga
Nov 13, 2012·Current Opinion in HIV and AIDS·Raph L HamersTobias F Rinke de Wit
Nov 24, 2012·AIDS Research and Human Retroviruses·Jamirah NazziwaUNKNOWN Chivtum Study Team
Dec 29, 2012·BMC Infectious Diseases·Steven J ReynoldsAndrew Kambugu
Jan 4, 2013·PloS One·Barbara CastelnuovoAndrew Kambugu
Aug 24, 2013·International Journal of STD & AIDS·A Nakiwogga-MuwangaR Colebunders
Jan 25, 2014·AIDS Research and Therapy·Amin S HassanJames A Berkley
Mar 13, 2014·BMC Health Services Research·Richard J LessellsUNKNOWN Southern African Treatment and Resistance Network (SATuRN)
Jun 25, 2014·AIDS Research and Human Retroviruses·Guinevere Q LeeJeffrey N Martin
Jan 13, 2015·The Journal of Infectious Diseases·Wan-Lin YangUNKNOWN Swiss HIV Cohort Study
Nov 17, 2015·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Castelnuovo BarbaraParkes-Ratanshi Rosalind
Dec 25, 2015·PloS One·Pontiano KaleebuUNKNOWN HIV Drug Resistance Working group
Feb 3, 2016·The Lancet Infectious Diseases·UNKNOWN TenoRes Study Group
Jun 21, 2016·Journal of the International AIDS Society·Barbara CastelnuovoSteven J Reynolds
Jun 28, 2016·The Journal of Antimicrobial Chemotherapy·T Sonia BoenderKim C E Sigaloff
Jul 13, 2016·JAMA : the Journal of the American Medical Association·Huldrych F GünthardPaul A Volberding
Nov 2, 2016·AIDS Research and Human Retroviruses·Steven J ReynoldsThomas C Quinn
Mar 24, 2017·The Journal of Antimicrobial Chemotherapy·L AssoumouUNKNOWN ANRS AC-11 Resistance Study Group
Nov 22, 2017·The Lancet Infectious Diseases·Lucas E HermansAnnemarie M J Wensing
Citations
Nov 27, 2018·The Journal of Antimicrobial Chemotherapy·Nadine BachmannUNKNOWN Swiss HIV Cohort Study
Jan 12, 2019·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Anna BaumannAmrei von Braun
Jul 4, 2019·Sexually Transmitted Infections·Gertrude NamaleJanet Seeley
Jun 2, 2020·AIDS Research and Human Retroviruses·Farouk SegujjaDeogratius Ssemwanga
Jul 6, 2019·The Journal of Antimicrobial Chemotherapy·Godfrey BarabonaTakamasa Ueno
Dec 8, 2019·AIDS Research and Therapy·Allan BuzibyeBarbara Castelnuovo